GlassScriptPhysician profile
De Ette Ray Vasques
NPI 1093743098
$19,270.80
in general payments reported to CMS, 2019-2025
20 companies · $12K in 2025
The $12K reported for 2025 was more than what 92% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2021: $14.53 · 2022: $1,768 · 2023: $1,916 · 2024: $2,658 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,000 · Travel and Lodging: $3,245 · Food and Beverage: $3,220 · Consulting Fee: $2,230 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,000.00 |
| Travel and Lodging | $3,244.88 |
| Food and Beverage | $3,219.70 |
| Consulting Fee | $2,230.00 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,719.38 | 2019-2025 | Da Vinci Surgical System |
| Integra Lifesciences Corporation | $4,302.36 | 2021-2025 | Codman Certas, Cusa Clarity, Integra |
| Stryker Corporation | $981.07 | 2019-2024 | Spy-Phi System, Chromophare F300 |
| Astrazeneca Pharmaceuticals LP | $265.79 | 2019-2025 | Enhertu, Lynparza |
| Glaxosmithkline, LLC. | $218.99 | 2023-2025 | Jemperli, Ojjaara |
| Genmab U.S., INC. | $187.46 | 2023-2025 | Tivdak |
| Janssen Biotech, INC. | $98.41 | 2023-2025 | Erleada, Darzalex, Balversa |
| Astellas Pharma US INC | $73.95 | 2024-2025 | Xospata, Veozah |
| Ethicon US, LLC | $70.38 | 2024-2025 | Vistaseal |
| Novartis Pharmaceuticals Corporation | $53.38 | 2024-2025 | |
| Daiichi Sankyo INC. | $52.22 | 2024-2025 | Enhertu |
| Eisai INC. | $46.86 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $38.97 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $35.57 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Emd Serono, INC. | $29.00 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.27 | 2024 | Verzenio |
| Genzyme Corporation | $20.43 | 2025 | |
| Taiho Oncology, INC. | $18.64 | 2024 | |
| Tesaro, INC. | $16.26 | 2019 | |
| Tersera Therapeutics LLC | $15.41 | 2025 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw De Ette Vasques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.